Key points are not available for this paper at this time.
Amivantamab (ami) is an EGFR-MET bispecific antibody with immune cell-directing activity. In MARIPOSA-2 (NCT04988295), ami plus carboplatin-pemetrexed (ami-chemo) significantly prolonged progression-free survival (PFS) vs chemo (HR, 0.48; P0.05), respectively. Updated results will include data from the NSCLC-SAQ and PROMIS-PF 8c instruments. Ami-chemo numerically prolonged TTSP vs chemo. More pts in the ITT population reported improved or stable functioning and absence of lung cancer-related symptoms for ami-chemo vs chemo in pts with EGFR-mutant advanced NSCLC after disease progression on osimertinib.
Tomasini et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: